Clinical trials: Lateral Canthal Lines
Lateral Canthal Lines, Crow's Feet
Dose Finding Study In Subjects With Crow's Feet
The purpose of this study is to establish the therapeutic range of ANT-1401 in the treatment of Crow's Feet.
- Trial name
- NCT01951742
- Testing
- ANT-1401, Vehicle
- Where
- 10 sites in United States
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Anterios Inc.
Lateral Canthal Lines, LCL, Crow's Feet
ET-01 in Subjects With Lateral Canthal Lines, LCL-209
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
- Trial name
- NCT03912805
- Testing
- botulinum toxin, Type A, Vehicle
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Eirion Therapeutics Inc.
Lateral Canthal Lines, Crow's Feet
Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
The purpose of this study is to evaluate the safety and efficacy of 2 sequential doses of RT001 compared to placebo gel to treat moderate to severe lateral canthal lines in adults.
- Conditions
- Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
- Trial name
- NCT00968942
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Revance Therapeutics, Inc.
Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of DaxibotulinumtoxinA for injection (DAXI for injection) in the treatment of Glabellar Lines (GL), Dynamic Forehead Lines (FHL)…
- Trial name
- NCT04259086
- Testing
- DaxibotulinumtoxinA for injection
- Where
- 8 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Revance Therapeutics, Inc.
Lateral Canthal Lines, Crow's Feet
Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
This study's objective is to evaluate if RT001 is safe and well-tolerated following two (2) sequential applications.
- Conditions
- Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
- Trial name
- NCT01124565
- Testing
- RT001
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Revance Therapeutics, Inc.
Lateral Canthal Lines, Crow's Feet
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
The purpose of this study is to evaluate the safety and efficacy of RT001 to treat moderate to severe lateral canthal lines in adults.
- Conditions
- Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
- Trial name
- NCT00888914
- Testing
- RT001, Vehicle Comparator
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Revance Therapeutics, Inc.
Lateral Canthal Lines, Crow's Feet
ET-01 in Subjects With Lateral Canthal Lines
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
- Trial name
- NCT03326856
- Testing
- botulinum toxin, Type A, Vehicle
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Eirion Therapeutics Inc.
Lateral Canthal Lines, LCL, Crow's Feet
ET-01 in Subjects With Lateral Canthal Lines, LCL-210
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
- Trial name
- NCT04985916
- Testing
- Vehicle, botulinum toxin, Type A
- Where
- 19 sites in United States
- Volunteers
- 280 people
- Sponsor
- Eirion Therapeutics Inc.
Lateral Canthal Lines, Crow's Feet Lines
BOTOX® in the Treatment of Crow's Feet Lines in China
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared with placebo in patients with moderate to severe crow's feet lines (lateral canthal lines).
- Trial name
- NCT02195687
- Testing
- botulinum toxin Type A, Normal Saline
- Where
- China
- Volunteers
- 417 people
- Sponsor
- Allergan
Skin Aging
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines
This is a safety and efficacy study of botulinum toxin type A in subjects with lateral canthal lines.
- Trial name
- REALISE 1 (NCT02580370)
- Testing
- Botulinum toxin type A
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Lines, Lateral Canthal Lines
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
To evaluate the long-term safety of MT10109L in the treatment of GL and/or LCL in participants with moderate to severe GL and/or LCL.
- Trial name
- NCT04157686
- Testing
- MT10109L Dose 1, MT10109L Dose 2, MT10109L Dose 1 + Dose 2
- Where
- 38 sites in United States, Belgium and 4 more
- Volunteers
- 957 people
- Sponsor
- Medy-Tox
Lateral Canthal Lines
MT10109L in the Treatment of Lateral Canthal Lines
To evaluate the safety and efficacy of MT10109L in the treatment of lateral canthal lines (LCL) in participants with moderate to severe LCL.
- Trial name
- NCT03785145
- Testing
- MT10109L
- Where
- 14 sites in United States, Russia and 1 more
- Volunteers
- 235 people
- Sponsor
- Medy-Tox
Lateral Canthal Lines (LCL), Perioral Rhytids
A Non-Interventional PMCF Study Evaluating Croma Revitalis for the Correction of Fine Lines
This study will serve to collect and analyze additional data on the use of the device croma revitalis for treatment of fine lines on the face including LCL and PR in the routine practice and as "real-world" performance.
- Trial name
- RICHER (NCT07492277)
- Where
- Austria
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Croma-Pharma GmbH
Lateral Canthal Lines
Treatment of Moderate to Severe Lateral Canthal Lines
The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe LCL.
- Trial name
- READY-2 (NCT04249687)
- Testing
- botulinum toxin
- Where
- 10 sites in United States, Canada
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Lateral Canthal Lines
Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)
Despite the wealth of information in the literature regarding the cosmetic applications of botulinum type A toxin (BoNT-A), and the widespread use of the BoNT-A for cosmetic applications, the number of randomised, controlled…
- Trial name
- NCT00247559
- Testing
- Botulinum toxin type A
- Where
- 9 sites in France, Germany and 1 more
- Volunteers
- 221 people
- Sponsor
- Ipsen
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines
The purpose of this study is to investigate the safety and efficacy of NT 201 (active ingredient: Botulinum (neuro)toxin type A, free from complexing proteins) in the combined treatment of wrinkles in the upper face (Upper Facial…
- Trial name
- ULTRA I (NCT04594213)
- Testing
- NT 201
- Where
- 12 sites in United States
- Volunteers
- 362 people
- Sponsor
- Merz North America, Inc.
Lateral Canthal Lines, Crow's Feet Lines
Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea
This is a postmarketing surveillance study in Korea to evaluate the safety and effectiveness of BOTOX® for lateral canthal lines (crow's feet lines) with or without simultaneous glabellar lines.
- Trial name
- NCT02248844
- Testing
- Botulinum Toxin Type A
- Where
- South Korea
- Volunteers
- 667 people
- Sponsor
- Allergan
Glabellar Lines, Lateral Canthal Lines
MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
To evaluate the safety and efficacy of MT10109L for the treatment of glabellar lines (GL) with or without concurrent treatment of lateral canthal lines (LCL) in participants with moderate to severe GL and LCL.
- Trial name
- NCT03721016
- Testing
- MT10109L
- Where
- 21 sites in United States, Canada and 2 more
- Volunteers
- 415 people
- Sponsor
- Medy-Tox
Lateral Canthal Lines, Crow's Feet
ET-01 in Subjects With Lateral Canthal Lines, LCL-208
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
- Trial name
- NCT03839693
- Testing
- botulinum toxin, Type A, Vehicle
- Where
- 5 sites in United States
- Volunteers
- 75 people
- Sponsor
- Eirion Therapeutics Inc.
Lateral Canthal Lines, Crow's Feet
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
The purpose of this study is to evaluate the efficacy and safety of a single administration of RT001 compared to placebo gel for the treatment of moderate to severe lateral canthal lines.
- Conditions
- Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
- Trial name
- NCT00968825
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Revance Therapeutics, Inc.